Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

Bluejay is working with JPMorgan Chase & Co., Jefferies Financial Group Inc. and Cantor Fitzgerald on the potential IPO, which could raise at least $150 million, they said. Have a confidential tip ...

The biotech is developing two candidates ... Another slice of the targeted IPO haul is earmarked for a proof-of-concept trial of F598, Alopexx’s other lead candidate. Sanofi licensed the ...

Sionna Therapeutics, a Waltham biotech targeting cystic fibrosis, raised $219.2 million in an IPO last month, and two other Bay State biotechs — Odyssey of Boston and Alopexx of Cambridge ...

Judge rules in favor of Aurion in IPO suit, a decision investor Alcon ... and will be responding accordingly,” Alcon told Fierce Biotech in an emailed statement. “As Aurion’s largest ...

Kirkland, Wash.-based Kestra Medical Technologies is aiming to raise about $150 million in its initial public offering, pricing shares between $14 and $16 ...

Many experts - be they venture capitalists or private equity investprs - shared their advice to biotech entrepreneurs navigating a tough funding envornment.